Health Care Technology
Rona Therapeutics Presents Phase 1 Data For RN0361, A Long-Acting APOC3-Targeting Sirna, At The American Heart Association 2025 Scientific Sessions
Share
NEW ORLEANS, Nov. 9, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, a long-acting Apolipoprotein C3 (ApoC3) siRNA. RN0361 achieved potent, durable reductions in ApoC3 and triglycerides (TG) lasting at least six months in a single dose first-in-human trial, establishing a potential best-in-class profile to prevent pancreatitis in severe hypertriglyceridemia (HTG) and reduce cardiovascular risk (CVD) from atherogenic lipoproteins. The data were presented today at the American Heart Association 2025 Scientific Sessions by Dr.Alex DePaoli, MD, CMO.
The randomized, placebo-controlled Single Ascending Dose (SAD) study in volunteers with baseline TG >80 mg/dl showed favorable tolerability, no serious adverse events, with mild, self-limited injection-site reactions (ISRs) and transient ALT and AST elevations typical of GalNAc-conjugated siRNAs. RN0361 demonstrated dose-responsive suppression of both ApoC3 and TG through Day 180, with a maximum 93% ApoC3 reduction and 69% triglyceride lowering. RN0361 also robustly reduced atherogenic lipoproteins, non-HDL-c, VLDL cholesterol and remnant cholesterol. No changes in fasting glucose or HbA1c were observed versus placebo.
Elevated ApoC3 drives triglyceride-rich lipoprotein accumulation, increasing risks of acute pancreatitis and cardiovascular disease, particularly in diabetes. Current therapies often fail to achieve sustained control in severe cases. RN0361's profound, six-month efficacy from a single dose may address this unmet need and marks a significant advance in lipid management.
"These data confirm RN0361's long-acting potency and favorable safety profile, supporting its advancement in Phase 2 studies in patients with hypertriglyceridemia," said Stella Shi, CEO. "By profoundly lowering ApoC3, TG and atherogenic lipids for at least six months after a single dose, RN0361 is an important potential therapeutic for the critical unmet need in severe HTG and CVD risk reduction."
About Rona Therapeutics
Rona Therapeutics is a world-leading RNAi therapeutics company dedicated to addressing cardiometabolic, obesity and degenerative diseases with next generation RNA technology platform. Since its inception in 2021, the Company has progressed four programs into the clinic leveraging its proprietary platform in delivery, multi-valency and oligo chemistry. The Company has raised around $200M from global blue-chip healthcare investors and strategic partners.
SOURCE Rona Therapeutics
Frequently Asked Questions
What is RN0361?
RN0361 is a long-acting Apolipoprotein C3 (ApoC3) siRNA being developed by Rona Therapeutics to treat severe hypertriglyceridemia and reduce cardiovascular risk.
What were the results of the Phase 1 trial?
The Phase 1 trial showed that RN0361 achieved potent, durable reductions in ApoC3 and triglycerides for at least six months after a single dose, with favorable tolerability.
What conditions is RN0361 designed to treat?
RN0361 is designed to prevent pancreatitis in severe hypertriglyceridemia and reduce cardiovascular risk associated with elevated triglycerides.
First published on Mon, Nov 10, 2025
Enjoyed what you've read so far? Great news - there's more to explore!
Stay up to date with the latest news, a vast collection of tech articles including introductory guides, product reviews, trends and more, thought-provoking interviews, hottest AI blogs and entertaining tech memes.
Plus, get access to branded insights such as informative white papers, intriguing case studies, in-depth reports, enlightening videos and exciting events and webinars from industry-leading global brands.
Dive into TechDogs' treasure trove today and Know Your World of technology!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.
Trending PR Newswire
Protecting Print Fleets: Symphion Addresses Complacency In Printer Endpoint Protection With Two New Offerings
School Specialty LLC Announces Acquisition Of Nasco Education U.S.
Scowtt Raises $12M Series A To Transform Performance Marketing With AI-Powered Advertising Platform
Unified.To Powers 550% API Usage Growth In Six Months Amid Rising AI Adoption
Broadridge's Distributed Ledger Repo Platform Processes $368 Billion In Average Daily Trade Volumes In November
Join Our Newsletter
Get weekly news, engaging articles, and career tips-all free!
By subscribing to our newsletter, you're cool with our terms and conditions and agree to our Privacy Policy.
Join The Discussion